EP3723761A4 - Forme pharmaceutique orale solide comprenant de la linagliptine - Google Patents

Forme pharmaceutique orale solide comprenant de la linagliptine Download PDF

Info

Publication number
EP3723761A4
EP3723761A4 EP18914956.0A EP18914956A EP3723761A4 EP 3723761 A4 EP3723761 A4 EP 3723761A4 EP 18914956 A EP18914956 A EP 18914956A EP 3723761 A4 EP3723761 A4 EP 3723761A4
Authority
EP
European Patent Office
Prior art keywords
linagliptin
dosage form
oral dosage
solid oral
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18914956.0A
Other languages
German (de)
English (en)
Other versions
EP3723761A2 (fr
Inventor
Ali TÜRKYILMAZ
Nur PEHLIVAN AKALIN
Merve ERGUN DONMEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP3723761A2 publication Critical patent/EP3723761A2/fr
Publication of EP3723761A4 publication Critical patent/EP3723761A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18914956.0A 2017-12-15 2018-12-14 Forme pharmaceutique orale solide comprenant de la linagliptine Pending EP3723761A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/20515A TR201720515A2 (tr) 2017-12-15 2017-12-15 Li̇nagli̇pti̇n i̇çeren bi̇r kati oral dozaj formu
PCT/TR2018/050812 WO2019203755A2 (fr) 2017-12-15 2018-12-14 Forme pharmaceutique orale solide comprenant de la linagliptine

Publications (2)

Publication Number Publication Date
EP3723761A2 EP3723761A2 (fr) 2020-10-21
EP3723761A4 true EP3723761A4 (fr) 2021-06-30

Family

ID=67900883

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18914956.0A Pending EP3723761A4 (fr) 2017-12-15 2018-12-14 Forme pharmaceutique orale solide comprenant de la linagliptine

Country Status (4)

Country Link
EP (1) EP3723761A4 (fr)
CA (1) CA3085455C (fr)
TR (1) TR201720515A2 (fr)
WO (1) WO2019203755A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022173406A1 (fr) * 2021-02-15 2022-08-18 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Procédé pour formulations de linagliptine ou d'un sel pharmaceutiquement acceptable de celle-ci

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092124A1 (fr) * 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Composition pharmaceutique contenant de la linagliptine et facultativement un inhibiteur sglt-2, et ses utilisations
US20140100236A1 (en) * 2012-10-09 2014-04-10 Boehringer Ingelheim International Gmbh Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
WO2014080383A1 (fr) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Composition pharmaceutique d'inhibiteurs de la dipeptidyl-peptidase-iv (dpp-iv) en association avec d'autres antidiabétiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013128379A2 (fr) 2012-02-27 2013-09-06 Dr. Reddy's Laboratories Limited Formes polymorphes cristallines de linagliptine
WO2014080384A1 (fr) 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Composition pharmaceutique de linagliptine
CN106138059A (zh) 2015-03-27 2016-11-23 天津汉瑞药业有限公司 一种稳定的利格列汀药物组合物
EP3156048A1 (fr) 2015-10-13 2017-04-19 Galenicum Health S.L. Composition pharmaceutique stable de linagliptine sous forme de comprimé à libération immédiate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092124A1 (fr) * 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Composition pharmaceutique contenant de la linagliptine et facultativement un inhibiteur sglt-2, et ses utilisations
US20140100236A1 (en) * 2012-10-09 2014-04-10 Boehringer Ingelheim International Gmbh Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
WO2014080383A1 (fr) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Composition pharmaceutique d'inhibiteurs de la dipeptidyl-peptidase-iv (dpp-iv) en association avec d'autres antidiabétiques

Also Published As

Publication number Publication date
WO2019203755A3 (fr) 2020-01-16
EP3723761A2 (fr) 2020-10-21
TR201720515A2 (tr) 2019-07-22
WO2019203755A2 (fr) 2019-10-24
CA3085455A1 (fr) 2019-10-24
CA3085455C (fr) 2022-08-16

Similar Documents

Publication Publication Date Title
GB2569961B (en) Pharmaceutical
GB2572126B (en) Pharmaceutical
GB2572125B (en) Pharmaceutical
EP3437646A4 (fr) Préparation orale présentant une exceptionnelle aptitude à l'élution
EP3565502A4 (fr) Irrigateur buccal
EP3603642A4 (fr) Préparation pharmaceutique
EP3402488A4 (fr) Formes galéniques solides orales de l'eslicarbazépine
EP3316848A4 (fr) Dispositifs buccaux
EP3590514A4 (fr) Préparation pharmaceutique
EP3281625A4 (fr) Préparation de film oral
EP3646866A4 (fr) Préparation pharmaceutique
IL271606A (en) Stomach-resistant controlled-release oral dosage forms
EP3411024A4 (fr) Forme pharmaceutique orale de film de loxapine
EP3727421A4 (fr) Compositions pharmaceutiques ayant une durée de libération choisie
EP3723761A4 (fr) Forme pharmaceutique orale solide comprenant de la linagliptine
ZA202006346B (en) Pharmaceutical preparation
PT3996688T (pt) Preparação farmacêutica
EP3697393A4 (fr) Formes posologiques pharmaceutiques
GB201901989D0 (en) Pharmaceutical combinations
EP3718503A4 (fr) Appareil de nettoyage buccal
EP3481379A4 (fr) Forme galénique orale contenant un enrobage extérieur à libération rapide
EP4074313A4 (fr) Préparation pharmaceutique solide
GB2561723B (en) A composition for oral administration
EP3641734A4 (fr) Forme pharmaceutique solide orale dissuasive d'abus
EP3903781A4 (fr) Préparation pharmaceutique

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200714

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210601

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/522 20060101AFI20210526BHEP

Ipc: A61K 47/00 20060101ALI20210526BHEP

Ipc: A61P 3/10 20060101ALI20210526BHEP

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231108